Skip to main content

22-02-2012 | Cardiology | Article

Intravenous iron improves life quality in iron-deficient heart failure patients


Free abstract

MedWire News: Health-related quality of life (HRQoL) in iron-deficient heart failure (HF) patients is significantly improved with intravenous (iv) ferric carboxymaltose (FCM) treatment, research suggests.

"In addition to improvements, we observed less deterioration in HRQoL in patients treated with FCM," report Josep Comin-Colet (Universitat Autonoma de Barcelona, Spain) and colleagues in the European Heart Journal.

They conducted a subanalysis of the Ferric Carboxymaltose Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial, which determined the effects of iv FCM in iron-deficient chronic HF patients.

The researchers randomly allocated 459 patients with reduced left ventricular ejection fraction (≤40%) and iron deficiency (serum ferritin <100 µg/L or <300 µg/L if transferritin saturation <20%), with or without anemia, to treatment with either FCM or placebo in a 2:1 ratio.

HRQoL was assessed at baseline and after 4, 12, and 24 weeks of therapy using the generic EuroQol (EQ-5D) and disease-specific Kansas City Cardiomyopathy Questionnaires (KCCQ).

At baseline, the mean EQ-5D Visual Analogue Scale score was 54.3 and the KCCQ overall summary score was 52.4.

At week 24, significant improvements from baseline with FCM treatment were observed for the five EQ-5D dimensions: mobility, self-care, pain/discomfort, anxiety/depression, and usual activity (p<0.006 for all).

FCM was also significantly associated with improved KCCQ mean scores in physical limitation, symptom burden, symptom frequency, symptom stability, and quality of life from week 4 onwards (p≤0.05) apart from self-efficacy and social limitation.

FCM treatment was associated with lower rates of deterioration in HRQoL throughout the study, the authors note.

They hypothesize that treatment with iv FCM may impact favorably on cardiac structure and remodeling to bring about the improved HRQoL in iron-deficient HF patients.

"Further research is required to confirm these findings and to determine the underlying mechanisms of the efficacy of iv iron in patients with [iron deficiency] and [chronic] HF," they conclude.

MedWire ( is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2012

By Piriya Mahendra

Related topics